Taiwan Liposome, which is developing lipid formulations of approved drugs for pain and eye disease, lowered the proposed deal size for its upcoming IPO and disclosed updated financials for the nine mo…
( read original story …)
The Taiwan NEWS
Taiwan Liposome, which is developing lipid formulations of approved drugs for pain and eye disease, lowered the proposed deal size for its upcoming IPO and disclosed updated financials for the nine mo…
( read original story …)